SPAS(SH:603168) Shang Hai Zheng Quan Bao·2025-04-10 19:13Group 1 - The company held its sixth supervisory board's seventh meeting on April 10, 2025, via communication, with all three supervisors present, and the meeting was deemed legal and effective [2][3]. - The supervisory board approved the proposal to waive the notification period for the meeting and agreed to sell the 100% equity of its wholly-owned subsidiary, Zhejiang Shapu Aisi Pharmacy Chain Co., Ltd., to Jiaxing Wanshoutang Pharmaceutical Chain Co., Ltd. for 500,000 RMB [4][8]. Group 2 - The decision to sell the subsidiary was made due to its continuous losses and misalignment with the company's strategic direction, aiming to focus on core business and optimize asset structure [9][34]. - The transaction does not constitute a related party transaction or a major asset restructuring as defined by regulations, and it does not require shareholder approval [10][34]. Group 3 - The target company, Zhejiang Shapu Aisi Pharmacy Chain Co., Ltd., was established in September 2015 with a registered capital of 10 million RMB and has been facing operational challenges [14][15]. - The transaction will not significantly impact the company's overall business development and is expected to enhance asset disposal returns while protecting shareholder interests [34].